Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys    MOR   DE0006632003


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

MorphoSys : Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
05/02/2019 | 04:13pm EDT

May 02, 2019 / 10:01 pm, CEST

Planegg/Munich, Germany, May 2, 2019

Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first three months' 2019 results on May 7, 2019 at 10:00pm CEST (9:00pm BST; 4:00pm EDT).

The Management team of MorphoSys AG will host a conference call and webcast on May 8, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys's first quarter interim statement 2019 and provide an outlook for 2019.

Date of the conference call: Wednesday, May 8, 2019
Time: 2:00pm CEST (1:00pm BST, 8:00am EDT)
Dial-in numbers (listen only)
Germany: +49 69 201 744 220
United Kingdom: +44 203 009 2470
USA: +1 877 423 0830
Participant PIN: 59832645#

Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.

The presentation slides and webcast link will be available at the Company's website at http://www.morphosys.com/conference-calls

A replay of the conference will also be available at the corporate website following the live event.

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 340 employees. More information at https://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys's expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for MOR208 and that data from MorphoSys's ongoing clinical research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys's reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys's Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys AG
Dr. Sarah Fakih
Head of Corporate Communications & IR

Alexandra Goller
Director Corporate Communications & IR

Dr. Julia Neugebauer
Director Corporate Communications & IR

Dr. Verena Kupas
Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404


MorphoSys AG published this content on 02 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 May 2019 20:12:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MORPHOSYS
09/19Animal health sector aims to emulate Zoetis biotech leap
09/19Biotech is going to the dogs - and big profits await
09/17MORPHOSYS : to Present at Upcoming Investor Conferences
09/17MORPHOSYS : to Present at Upcoming Investor Conferences
09/17MORPHOSYS : Licensee Janssen Submits Biologics License Application to U.S. FDA o..
09/16MORPHOSYS : Licensee Janssen Submits Biologics License Application to U.S. FDA o..
09/16MORPHOSYS : Licensee Janssen Submits Biologics License Application to U.S. FDA o..
09/12MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
09/10MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
09/06MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
More news
Financials (EUR)
Sales 2019 69,9 M
EBIT 2019 -101 M
Net income 2019 -94,1 M
Finance 2019 351 M
Yield 2019 -
P/E ratio 2019 -33,9x
P/E ratio 2020 -35,1x
EV / Sales2019 42,8x
EV / Sales2020 26,2x
Capitalization 3 342 M
Duration : Period :
MorphoSys Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 119,92  €
Last Close Price 105,60  €
Spread / Highest target 42,0%
Spread / Average Target 13,6%
Spread / Lowest Target -23,3%
EPS Revisions
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS18.94%3 677
LONZA GROUP35.89%25 846
CELLTRION, INC.--.--%18 845